2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

dc.contributor.authorLosa, F.
dc.contributor.authorIglesias, L.
dc.contributor.authorPané, M.
dc.contributor.authorSanz, J.
dc.contributor.authorNieto, B.
dc.contributor.authorFusté, V.
dc.contributor.authorde la Cruz‑Merino, L.
dc.contributor.authorConcha, Ángel
dc.contributor.authorBalañá, Carme
dc.contributor.authorMatias-Guiu, Xavier
dc.date.accessioned2021-03-22T09:28:42Z
dc.date.available2021-03-22T09:28:42Z
dc.date.issued2018
dc.description.abstractCancer of unknown primary (CUP) is defned as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They difer from other primary tumours in their biological features and how they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin, but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability. Depending on the type of study done, CUP can account for 2–9% of all cancer patients, mostly 60–75 years old. This article reviews the main clinical, pathological, and molecular studies conducted to analyse and determine the origin of CUP.The main strategies for patient management and treatment, by both clinicians and pathologists, are also addressed.ca_ES
dc.description.sponsorshipThe authors are grateful for the editorial assistance of Dr. Fernando Sánchez-Barbero of HealthCo (Madrid, Spain) in the production of this manuscript. SEOM and SEAP are grateful for the fnancial support for this project in the form of unrestricted grants from Ferrer Diagnostic, OncoDNA and Foundation Medicine/Roche.ca_ES
dc.identifier.doihttps://doi.org/10.1007/s12094-018-1899-z
dc.identifier.idgrec034851
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/10459.1/70821
dc.language.isoengca_ES
dc.publisherSpringerca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1007/s12094-018-1899-zca_ES
dc.relation.ispartofClinical & Translational Oncology, 2018, vol. 20, núm. 11, p.1361-1372ca_ES
dc.rightscc-by (c) Losa et al., 2018ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCancer of unknown primaryca_ES
dc.subjectDiagnosisca_ES
dc.subjectImmunohistochemistryca_ES
dc.subjectBiopsyca_ES
dc.subjectPrognosisca_ES
dc.subjectChemotherapyca_ES
dc.subjectMolecular pathologyca_ES
dc.subjectHistopathologyca_ES
dc.title2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primaryca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
034851.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: